Nexthera Capital LP bought a new position in shares of Zafgen Inc (NASDAQ:ZFGN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 171,435 shares of the biopharmaceutical company’s stock, valued at approximately $792,000. Nexthera Capital LP owned approximately 0.62% of Zafgen at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC raised its position in Zafgen by 18.3% in the fourth quarter. Acadian Asset Management LLC now owns 104,014 shares of the biopharmaceutical company’s stock valued at $481,000 after purchasing an additional 16,072 shares during the period. Mangrove Partners increased its position in shares of Zafgen by 4.9% during the fourth quarter. Mangrove Partners now owns 587,629 shares of the biopharmaceutical company’s stock worth $2,715,000 after acquiring an additional 27,644 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Zafgen by 91.1% during the fourth quarter. Two Sigma Investments LP now owns 61,048 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 29,101 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Zafgen by 139.1% during the fourth quarter. Bank of New York Mellon Corp now owns 87,571 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 50,939 shares during the last quarter. Finally, OxFORD Asset Management LLP grew its stake in Zafgen by 65.0% in the third quarter. OxFORD Asset Management LLP now owns 171,112 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 67,394 shares in the last quarter. 52.29% of the stock is owned by institutional investors and hedge funds.
In other Zafgen news, insider Thomas E. Hughes sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 21.20% of the stock is currently owned by corporate insiders.
A number of equities analysts have commented on ZFGN shares. Zacks Investment Research downgraded Zafgen from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $20.00 price target (up previously from $11.00) on shares of Zafgen in a report on Wednesday, March 7th.
Zafgen Inc (NASDAQ:ZFGN) traded up $0.13 during trading on Tuesday, hitting $7.17. 5,590 shares of the stock traded hands, compared to its average volume of 229,810. The stock has a market cap of $200.35, a PE ratio of -3.69 and a beta of -0.65. Zafgen Inc has a fifty-two week low of $3.21 and a fifty-two week high of $10.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 14.39 and a current ratio of 14.39.
Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, March 6th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.09. research analysts anticipate that Zafgen Inc will post -2.2 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Nexthera Capital LP Acquires New Holdings in Zafgen Inc (NASDAQ:ZFGN)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/20/nexthera-capital-lp-takes-792000-position-in-zafgen-inc-zfgn.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.